In 2011, IDIBELL have continued increasing its scientific output focused on improving the health of people. Our researchers have continued publishing in top international journals and participating in leading research projects. The annual report 2011 highlights the most important facts of the year at the centre. A new feature of this edition is the inclusion […]
Annual Report 2011 Read More »
IT-LIVER is a 3.3-million Euros project funded by European Commission under its FP7 Marie Curie Actions. This project will be carried out by 8 academic-research institutions and 4 industrial partners from six European countries. The coordinator of IT-LIVER is Isabel Fabregat, head of the Biological clues of the invasive and metastatic phenotype group of the
IDIBELL leads a European project on developing strategies against liver disease Read More »
The MED12 oncogene is essential in monitoring response to new cancer drugs, according to the study published in Cell and leaded by researchers at the IDIBELL and ICO in collaboration with researchers from the Netherlands Cancer Institute (NKI) in Amsterdam. This research, published in Cell, has shown that MED12 oncogene plays a key role in
The MED12 oncogene, key in response to cancer drugs Read More »
Some animal models developed by researchers at the Institute of Biomedical Research of Bellvitge (IDIBELL) and the Catalan Institute of Oncology (ICO) has served to validate the effectiveness of a new drug against ovarian cancer resistant to cisplatin. The multidisciplinary work, done in collaboration with the biopharmaceutical company Pharmamar, was published in the journal Clinical
Last October 5th took place in the University of Barcelona (Bellvitge Campus) the conference “Musical practice for the development of speech segmentation abilities, behavioural and electrophysiological evidences”, by PhD. Clément François, researcher of the Institut de Neurosciences de la Méditerranée CNRS and Aux-Marseille Universities (France). The Cognition and Brain plasticity group, from the UB and
Clément François: “We must promote music in children” Read More »
New advances in anti-aging research attended the “Divendres” program on TV3 last October 3. After an introduction about aging and how our habits determined up to 90% of our life, the journalist Xavi Coral talked with Dr. Manel Esteller, director of the Cancer Epigenetics and Biology Program in the Bellvitge Biomedical Research Institute (IDIBELL), Professor
Aging and epigenetics in “Divendres” (TV3) Read More »
A team of researchers from the Institute of Industrial and Control Engineering (IOC) of the Universitat Politècnica de Catalunya · BarcelonaTech (UPC) and the Pulmonology Research Group of the Bellvitge Biomedical Research Institute (IDIBELL) has patented an improved virtual bronchoscopy system designed to enhance endoscopic examination of peripheral lung lesions, that is, small nodules located
The team led by Manel Esteller, director of the Cancer Epigenetics and Biology Program in the Bellvitge Biomedical Research Institute (IDIBELL), Professor of Genetics at the University of Barcelona and ICREA researcher, has identified epigenetic changes that occur in adult stem cells to generate different body tissues. The finding is published this week in The
Adult stem cells change their epigenome to generate new organs Read More »
The Molecular Genetic Diagnosis Centre at IDIBELL participates in the development of a genetic test that allows analyzing 285 genes associated with various neurological diseases, using a sophisticated mass sequencing technology. The test can reduce threefold the time to obtain the results and decreases in nearly a hundred times the price of the standard technique,
Developed a new test to diagnose genetic susceptibility to neuropathy Read More »
